FLNA NASDAQ
Filana Therapeutics, Inc.
1W: +24.4%
1M: +8.6%
3M: -25.5%
YTD: -59.9%
$0.93
-0.03 (-3.53%)
Weekly Expected Move ±25.1%
$0
$1
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$45.0M
52W Range0.67-4.98
Volume1,674,643
Avg Volume1,487,762
Beta-0.70
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEORichard Jon Barry
Employees19
SectorHealthcare
IndustryBiotechnology
IPO Date2000-07-14
Websitefilanatx.com
6801 N. Capital of Texas Highway
Austin, TX 78731
US
Austin, TX 78731
US
512 501 2444
About Filana Therapeutics, Inc.
Filana Therapeutics, Inc. is a company dedicated to pioneering new pharmaceutical products and diagnostic technologies. A key area of its research is focused on creating potential treatments for Alzheimer's disease, including the investigational compounds PTI-125 and PTI-125Dx. Established by Remi Barbier in May 1998, the firm maintains its principal office in Austin, Texas.
Latest News
Filana CEO buys 306,813 shares
Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy
Cassava Sciences GAAP EPS of -$0.18 beats by $0.05
Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update
Filana Therapeutics Reports Q1 2026 Financial Results and Business Update
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Barry Richard | P-Purchase | 100,000 | $0.92 | 2026-09-30 |
| Barry Richard | P-Purchase | 206,813 | $0.90 | 2026-09-29 |
| Barry Richard | P-Purchase | 93,091 | $0.84 | 2026-09-28 |